ADMA Biologics, Inc.ADMANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +59.06% | +40.22% | +13.80% | +12.00% | +18.39% |
| Gross Profit Growth | +103.73% | +56.23% | +17.01% | +26.76% | +40.24% |
| EBITDA Growth | +0.00% | +53.99% | +5.54% | +21.39% | +65.08% |
| Operating Income Growth | +169.25% | +59.85% | +9.18% | +28.69% | +63.74% |
| Net Income Growth | +0.00% | +51.10% | +6.73% | +1.45% | -55.87% |
| EPS Growth | +0.00% | +41.39% | +0.00% | +0.00% | -55.32% |
| EPS Diluted Growth | +0.00% | +46.08% | +7.69% | +0.00% | -56.52% |
| Weighted Average Shares Growth | +4.63% | +3.89% | +3.90% | +1.72% | +0.65% |
| Weighted Average Shares Diluted Growth | +8.82% | +3.49% | +2.66% | -0.06% | -0.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +185.38% | +0.00% | -53.69% | -46.89% | -29.03% |
| Free Cash Flow Growth | +189.41% | +0.00% | -57.05% | -104.48% | -27.19% |
| Receivables Growth | +82.34% | +100.34% | +264.38% | +174.58% | +216.86% |
| Inventory Growth | -1.54% | -3.12% | +6.48% | +14.47% | +21.28% |
| Asset Growth | +48.45% | +45.51% | +48.35% | +45.59% | +27.74% |
| Book Value per Share Growth | +146.71% | +133.85% | +103.62% | +82.80% | +35.88% |
| Debt Growth | -41.93% | -42.01% | -40.72% | -25.37% | -2.72% |
| R&D Expense Growth | -12.23% | +83.56% | +84.11% | +270.87% | +251.92% |
| SG&A Expenses Growth | +50.09% | +53.97% | +33.75% | +24.18% | +0.84% |